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Introduction: As of Feb 11, 2020, the total number of patients with laboratory-confirmed SARS-CoV-2 infection across China has reached over 40000 and are still growing. 1 the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.02.13.20022830 doi: medRxiv preprint Results: Two cohorts contained SARS-CoV-2-negative (SN) patients (n=53) and SARS-CoV-2-positive (SP) patients (n=52), respectively. The differences in clinical and laboratory findings between the two cohorts were univariately and multivariately analyzed (Table1). No significant differences were found in gender. SP patients (average age 57) was older than SN patients (average age 51, p=0.015). SN patients had a higher rate of other respiratory pathogens infection (34% vs 9.6%, p=0.005). All the patients had pneumonia-like clinical symptoms including fever and respiratory symptoms, whose distribution was similar in the two cohorts.
In laboratory findings, the rates of "normal or decreased number of leukocytes" and "lymphopenia" that were used for defining suspected patients by the current guidelines, were not different between these two cohorts. Intriguingly, eosinopenia (<0.02 ×10 9 / L) was observed in the majority of SP patients (78.8 %), in stark contrast to 35.8 % in SN patients (p ＜0.001). Consistently, the average eosinophil counts across SP patients (0.02 ×10 9 / L) was significantly lower than that of SN patients (0.05 ×10 9 / L, p=0.004).
The performance of eosinopenia as a predictor for SARS-CoV-2 infection was then determined in the presence of symptoms ( Table 2 ). The inclusion of leukocyte counts (normal or decreased number) had no significant diagnostic value. Notably, the inclusion of eosinopenia remarkably improved the sensitivity and specificity to 78.8% and 64.2%, respectively, much higher than the inclusion of lymphopenia (48.1% and 52.8%). Further, the combination of other blood parameters (leukocytes and/ or lymphopenia) with eosinopenia increased selectivity but reduced sensitivity.
Discussion: Eosinopenia can be observed in typhoid fever or as a response to glucocorticoid.
In previous clinical reports on SARS-CoV, MERS-CoV and current SAR-CoV-2, 4-6 changes in eosinophils in peripheral blood were usually omitted. Our study showed that eosinopenia appeared in the majority of SP patients. The mechanisms underlying such eosinopenia were currently unclear and warrant further study.
Since the data was collected at patients' first medical visit, eosinopenia was presumed to be an early event in patients' clinical course, possibly prior to emergence of characteristic radiological findings. Combined with fever and respiratory symptoms, eosinopenia as a parameter in routine blood tests might be capable of facilitating rapid identification of highlysuspected cases from mixed patients at triage in fever clinics. These quickly-identified suspected patients would be recommended to (1) receive the priority for radio-diagnosis and laboratory-definitive diagnosis, (2) be isolated in designated wards without any delay to avoid potential virus spreading, (3) and receive empirical antiviral treatment (as of now no consensus All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.02.13.20022830 doi: medRxiv preprint over usage of antiviral agents) to prevent aggravation. The additional inclusion of eosinopenia may further refine the laboratory diagnostic criteria recommended by the current guidelines. Numbers are absolute cell counts (10 9 / L). PPV, positive predictive value; NPV, negative predictive value.
